search
Back to results

A Pilot Study of Ambulatory Heart Rate Variability Biofeedback for Substance Use Disorder

Primary Purpose

Substance Use Disorders

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Heart rate variability biofeedback + treatment as usual
Treatment as usual only
Sponsored by
Massachusetts General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Substance Use Disorders focused on measuring Heart rate variability biofeedback, Just in time, Autonomic nervous system, Substance use disorder, Addiction recovery

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • ≥18 years of age
  • Own a smartphone
  • English proficiency
  • DSM 5 diagnosis of substance use disorder
  • In the first year of a current substance use disorder recovery attempt with a goal of total alcohol and other drug abstinence

Exclusion Criteria:

  • Medical history of severe cardiac arrhythmia
  • Active psychosis

Sites / Locations

  • Massachusetts General HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Heart rate variability biofeedback + treatment as usual

Treatment as usual only

Arm Description

The experimental group will participate in 8 weeks of heart rate variability biofeedback practice using the Lief heart rate variability biofeedback Smart Patch and smartphone app + treatment as usual. Participants will be asked to, 1) wear the Lief Smart Patch for at least 8 hours per day, 2) do 15mins of scheduled heart rate variability biofeedback practice daily, and 3) use it as needed in response to negative affect in-the-moment.

The control group will participate in 8 weeks of treatment as usual only.

Outcomes

Primary Outcome Measures

Heart rate variability biofeedback engagement
Heart rate variability biofeedback (HRVB) engagement reflected by HRVB practice time. As a general benchmark of intervention uptake success, we will accept ≥50% engagement/adherence to scheduled practice (i.e., 15mins daily) with consideration given to both number of days practiced and time practiced each day. We will also accept ≥50% in-the-moment practice as indicative of engagement/adherence, based on the ratio of just-in-time practice prompts responded to vs. ignored and the number of days participants engaged in in-the-moment HRVB practice.
Day-level substance use
Day-level substance use measured by ecological momentary assessment
Day-level negative affect
Day-level negative affect measured by ecological momentary assessment
Day-level craving
Day-level craving measured by ecological momentary assessment
Day-level positive affect
Day-level positive affect measured by ecological momentary assessment
8-week substance use
Substance use over the 8-week intervention period expressed as percent days abstinent measured by ecological momentary assessment
Change negative affect
Change in negative affect measured by ecological momentary assessment over the 8-week intervention period, modeled using time-varying effects modeling (TVEM).
Change craving
Change in craving measured by ecological momentary assessment over the 8-week intervention period, modeled using time-varying effects modeling (TVEM).
Change positive affect
Change in positive affect measured by ecological momentary assessment over the 8-week intervention period, modeled using time-varying effects modeling (TVEM).

Secondary Outcome Measures

Full Information

First Posted
July 4, 2022
Last Updated
January 6, 2023
Sponsor
Massachusetts General Hospital
Collaborators
Colorado State University
search

1. Study Identification

Unique Protocol Identification Number
NCT05454657
Brief Title
A Pilot Study of Ambulatory Heart Rate Variability Biofeedback for Substance Use Disorder
Official Title
A Pilot Study of Ambulatory Heart Rate Variability Biofeedback for Substance Use Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 15, 2022 (Actual)
Primary Completion Date
July 2024 (Anticipated)
Study Completion Date
July 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
Collaborators
Colorado State University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Heart rate variability biofeedback (HRVB) is an biobehavioral intervention involving rhythmic breathing at resonance frequency that stimulates cardiovascular regulatory systems to help individuals better regulate affect and bolster cognitive control. This intervention has already shown its potential as a substance use disorder (SUD) treatment tool, but practical limitations of its accessibility, labor intensiveness, and cost have previously prevented this intervention from going to scale. Second-generation, ambulatory HRVB technology, however, has overcome these limitations and now allows patients to practice HRVB in-the-moment when its needed most. This study is testing the efficacy of second-generation, ambulatory HRVB for the first time with individuals with SUD.
Detailed Description
Alcohol and other drug use (AOD) lapses in early substance use disorder (SUD) recovery typically arise from interactions between aversive affective states and stressors that together elicit urges to use. A central goal of first-line cognitive-behavioral SUD treatments is to strengthen affective and cognitive control to increase individuals' ability to override impulses to use AOD. Yet certain automatic physiological processes compromised by SUD dynamically interact with internal affective states and environmental cues to undermine effortful cognitive control and outcompete cognitive goals to avoid substance use. Heart rate variability biofeedback (HRVB) is a biobehavioral intervention involving rhythmic breathing at resonance frequency (RF) that stimulates the body's baroreflex mechanism to offset these psychophysiological deficits. The autonomic normalization effected by RF breathing is thought to bolster cognitive control efforts by interrupting or dampening automatic-visceral reactions that can undermine treatment gains, and in doing so support better decision-making, motivation, reductions in craving, and shifts in attention allocation. Previous studies of HRVB have focused on positive behavioral effects that accrue over a series of weeks or months, rather than 'in-the-moment'. These chronic behavior changes, although clinically valuable, are labor and time intensive to elicit, reducing the likelihood of large-scale uptake of the intervention. Further, first-generation HRVB's regular daily practice model is likely to only partially mitigate the intense momentary bouts of emotion dysregulation that are triggers for AOD use in those in early SUD recovery. In contrast, recent studies have demonstrated that a brief exposure to RF breathing in anticipation of psychosocial stress, or during induced stress, helps to control physiological arousal, reduce state anxiety, and improve cognitive performance. It is posited that such bursts of in-the-moment HRVB practice could serve as a potent SUD treatment tool that helps individuals self-regulate emotions when needed most. Recent advances in the field have given rise to small, lightweight, wearable biosensors that can allow wearers to do HRVB on-the-go. These devices also have the capacity to function as a just-in-time intervention by prompting in-the-moment HRVB practice when autonomic hyperarousal is detected, to buffer salient triggers and urges to use AOD. This research builds on a body of preliminary work speaking to HRVB's potential as an addendum to first-line SUD treatments by exploring for the first time in this disorder this second-generation, ambulatory, HRVB technology. Specific aims of this research include, 1) assessing ambulatory HRVB's uptake by individuals with SUD, 2) testing day-level effects of in-the-moment HRVB practice on affective states and substance use, and 3) testing the accumulative effects of scheduled daily HRVB practice, in-the-moment HRVB practice, and their interaction, on substance use.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Substance Use Disorders
Keywords
Heart rate variability biofeedback, Just in time, Autonomic nervous system, Substance use disorder, Addiction recovery

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Heart rate variability biofeedback + treatment as usual vs. treatment as usual only
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Heart rate variability biofeedback + treatment as usual
Arm Type
Experimental
Arm Description
The experimental group will participate in 8 weeks of heart rate variability biofeedback practice using the Lief heart rate variability biofeedback Smart Patch and smartphone app + treatment as usual. Participants will be asked to, 1) wear the Lief Smart Patch for at least 8 hours per day, 2) do 15mins of scheduled heart rate variability biofeedback practice daily, and 3) use it as needed in response to negative affect in-the-moment.
Arm Title
Treatment as usual only
Arm Type
Active Comparator
Arm Description
The control group will participate in 8 weeks of treatment as usual only.
Intervention Type
Device
Intervention Name(s)
Heart rate variability biofeedback + treatment as usual
Intervention Description
Heart rate variability biofeedback is a biobehavioral intervention involving rhythmic breathing at resonance frequency (RF) that stimulates the baroreflex and increases heart rate variability. Treatment as usual may include any outpatient substance use disorder treatment or mutual-help group participation.
Intervention Type
Behavioral
Intervention Name(s)
Treatment as usual only
Intervention Description
Treatment as usual may include any outpatient substance use disorder treatment or mutual-help group participation.
Primary Outcome Measure Information:
Title
Heart rate variability biofeedback engagement
Description
Heart rate variability biofeedback (HRVB) engagement reflected by HRVB practice time. As a general benchmark of intervention uptake success, we will accept ≥50% engagement/adherence to scheduled practice (i.e., 15mins daily) with consideration given to both number of days practiced and time practiced each day. We will also accept ≥50% in-the-moment practice as indicative of engagement/adherence, based on the ratio of just-in-time practice prompts responded to vs. ignored and the number of days participants engaged in in-the-moment HRVB practice.
Time Frame
8 weeks
Title
Day-level substance use
Description
Day-level substance use measured by ecological momentary assessment
Time Frame
8 weeks
Title
Day-level negative affect
Description
Day-level negative affect measured by ecological momentary assessment
Time Frame
8 weeks
Title
Day-level craving
Description
Day-level craving measured by ecological momentary assessment
Time Frame
8 weeks
Title
Day-level positive affect
Description
Day-level positive affect measured by ecological momentary assessment
Time Frame
8 weeks
Title
8-week substance use
Description
Substance use over the 8-week intervention period expressed as percent days abstinent measured by ecological momentary assessment
Time Frame
8 weeks
Title
Change negative affect
Description
Change in negative affect measured by ecological momentary assessment over the 8-week intervention period, modeled using time-varying effects modeling (TVEM).
Time Frame
8 weeks
Title
Change craving
Description
Change in craving measured by ecological momentary assessment over the 8-week intervention period, modeled using time-varying effects modeling (TVEM).
Time Frame
8 weeks
Title
Change positive affect
Description
Change in positive affect measured by ecological momentary assessment over the 8-week intervention period, modeled using time-varying effects modeling (TVEM).
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: ≥18 years of age Own a smartphone English proficiency DSM 5 diagnosis of substance use disorder In the first year of a current substance use disorder recovery attempt with a goal of total alcohol and other drug abstinence Exclusion Criteria: Medical history of severe cardiac arrhythmia Active psychosis
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
David Eddie, Ph.D.
Phone
617-643-9194
Email
deddie@mgh.harvard.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Marina Nguyen, B.A.
Phone
617-732-8140
Email
mnguyen64@mgh.harvard.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Eddie, Ph.D.
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114-4714
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
617-643-9194

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Pilot Study of Ambulatory Heart Rate Variability Biofeedback for Substance Use Disorder

We'll reach out to this number within 24 hrs